IMPROVE-IT Go-Ahead Gives Merck Temporary Reprieve On Vytorin
This article was originally published in The Pink Sheet Daily
Large outcomes study of Vytorin (ezetimibe/simvastatin) is allowed to carry on, reassuring investors that significant safety problems are unlikely to emerge. The development coincides with release of full results from the outcomes trial HPS2-THRIVE, in which Merck’s niacin-containing Tredaptive proved unsafe as well as ineffective.
You may also be interested in...
Merck’s recent sale of its consume health business to Bayer involved a side bet on a new class of antihypertensive, which could mark a return to cardiovascular for Merck.
The strong efficacy and sound safety data coming out of the Phase III programs presented at ACC have all eyes on the commercial opportunity for the PCSK9 inhibitor class. Ongoing outcomes trials and market impact of new cholesterol guidelines sparked discussion, and leading sponsors Amgen and Sanofi/Regeneron talked about the potential populations and differences in the devices and dosing of evolocumab and alirocumab.
Merck insists it is committed to its cardiovascular franchise, but the company has had to halt the development of several CV assets and has been plagued by poor trial results for others.